Roche, Blueprint catch up with Lilly as Gavreto snags FDA thyroid cancer nod
When Roche and Blueprint Medicine’s Gavreto got the FDA go-ahead in September to challenge Eli Lilly’s first-to-market Retevmo, the newer entrant lacked an indicatio...



